Tin tức & Cập nhật

Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).

Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.